1. The Question
The labeled intubating dose of rocuronium spans 0.6 to 1.2 mg/kg; with an ED95 of about 0.3 mg/kg, the usual RSI dose of 1.0 mg/kg is more than three times the ED95. Emergency and critical care literature has spent the better part of a decade circling the same question: does pushing more than that — 1.2 mg/kg and above — meaningfully raise the odds of a successful first attempt, or does it just prolong paralysis for no benefit?
Why this isn't trivial: first-attempt success matters. Failed first attempts are linked to more hypoxemia, more hemodynamic instability, and more esophageal intubations — the stakes of the dosing decision are real, not academic.
2. The New Data: DEVICE/PREOXI Secondary Analysis
April et al. pooled data from two large multicenter randomized trials — DEVICE (video vs. direct laryngoscopy) and PREOXI (preoxygenation strategy) — which together enrolled critically ill adults undergoing emergency tracheal intubation across 9 EDs and 24 ICUs. This wasn't a new trial; it was a propensity-matched secondary analysis of rocuronium dosing already captured in that pooled dataset.
The numbers: of 2,440 total trial participants, 1,822 received rocuronium — 720 (39.5%) at high dose (>1.2 mg/kg) and 1,102 (60.5%) at standard dose (≤1.2 mg/kg).
| Population | Adjusted relative risk of first-attempt success |
|---|---|
| Overall | 1.06 (95% CI 1.01–1.11) — high-dose favored, modestly |
| ED intubations only | 0.97 (95% CI 0.90–1.04) — no association |
| ICU intubations only | 1.12 (95% CI 1.05–1.19) — clear association |
The finding that matters most isn't the headline number — it's the interaction. The benefit of high-dose rocuronium essentially disappeared in the ED subgroup and persisted in the ICU subgroup, with a statistically significant interaction (p=0.002). The overall "high-dose wins" headline obscures a split result underneath it.
The authors' own framing: this is a secondary analysis with real potential for unmeasured confounding — sicker or harder-airway patients may have been dosed differently for reasons the data can't capture — and they explicitly call for a randomized trial rather than presenting this as definitive.
3. What Came Before: Registry Evidence
The DEVICE/PREOXI analysis didn't emerge in a vacuum — it lands on top of a decade of ED-registry data pointing the same general direction, with one recurring wrinkle: the benefit tends to concentrate in direct laryngoscopy, not video laryngoscopy.
| Study | Finding |
|---|---|
| NEAR registry (Levin et al., 2021) | 8,034 ED rocuronium intubations across 25 centers. First-attempt success climbed with dose: 88.4% (<1.0 mg/kg), 88.1% (1.0–1.1), 89.7% (1.2–1.3), 92.2% (≥1.4 mg/kg). |
| NEAR, device-stratified | With direct laryngoscopy, ≥1.4 mg/kg carried adjusted OR 1.9 (95% CI 1.3–2.7) for first-attempt success vs. the 1.0–1.1 mg/kg reference. With video laryngoscopy, first-attempt success was statistically similar across every dosing range — the dose-response relationship was a direct-laryngoscopy phenomenon. |
| Single-center retrospective, ED/ICU (2026) | First-attempt success 100% with >1.2 mg/kg vs. 89.5% with ≤1.2 mg/kg (p<0.01), with fewer mean attempts (1 vs. 1.1). |
Put the device-stratification finding next to the DEVICE/PREOXI ED-vs-ICU split and a pattern starts to emerge: the benefit of higher rocuronium dosing looks concentrated in situations without a camera doing some of the work for you — direct laryngoscopy in the NEAR data, ICU intubations (often without immediate video backup or by a wider range of operator experience) in the newer analysis. That's a hypothesis worth testing prospectively, not yet a proven mechanism.
4. The Tradeoff: Why More Isn't Free
"Go big" has a real cost, and it isn't hemodynamic — rocuronium is comparatively cardiostable. The cost is time: a bigger dose buys a modestly faster onset in exchange for a much longer paralysis.
Onset: 1.2 mg/kg shortens onset to roughly 45–60 seconds, only marginally faster than 0.9–1.0 mg/kg — one dose-finding study found no further improvement in intubating conditions at 60 seconds going from 0.9 to 1.2 mg/kg.
Recovery: the same study found time to spontaneous recovery was meaningfully prolonged after 1.2 mg/kg compared with 0.6 and 0.9 mg/kg — the relationship between post-tetanic count and return of the first twitch stretched out at the higher dose.
| Consideration | Why it matters |
|---|---|
| Masked neuro exam | In the ICU population where this analysis found its signal, a longer paralysis window is a longer window without a reliable neurologic exam in a critically ill patient — a real cost in exactly the population where the dosing benefit showed up. |
| Reversal cost and kinetics | Sugammadex reverses high-dose rocuronium effectively, but the required dose scales with the block depth — reversing a profound block from 1.2 mg/kg needs a larger sugammadex dose than reversing a lighter block, with a real cost difference, not just a kinetic one. |
| Interpatient variability | Elderly and hepatically impaired patients already run a prolonged duration of action at standard doses — stacking a high dose on top of reduced clearance compounds unpredictably. |
None of this argues against high-dose rocuronium where it's indicated — it argues against treating "more is simply better" as a costless decision. The DEVICE/PREOXI analysis measured first-attempt success; it did not measure how long each patient sat paralyzed afterward, and that's not a trivial omission for an ICU population.
5. Practical Synthesis
In the ED, especially with video laryngoscopy available: the evidence for going above 1.2 mg/kg is weak-to-absent in this dataset. Standard dosing (1.0–1.2 mg/kg) is reasonable as a default.
In the ICU, or anywhere direct laryngoscopy is the primary tool: the signal for high-dose rocuronium improving first-attempt success is real across multiple analyses now — worth considering, especially in a predicted difficult airway, while accounting for the prolonged paralysis it buys you.
The honest summary a trainee should walk away with: this is genuinely unsettled, the ED/ICU split is the most clinically actionable detail in the whole story, and an RCT is the reasonable next step the authors themselves are calling for — not a reason to change practice unilaterally today.
6. Quick Reference Card & Primary Sources
| Setting | Bottom line from current evidence |
|---|---|
| ED, video laryngoscopy available | Standard dose (1.0–1.2 mg/kg) reasonable; high-dose benefit not shown in this population |
| ED, direct laryngoscopy | Registry data (NEAR) suggests a real dose-response benefit at ≥1.4 mg/kg |
| ICU intubation | High-dose (>1.2 mg/kg) associated with higher first-attempt success (RR 1.12) — the strongest signal in the current data |
| Elderly / hepatic impairment / anticipated difficult airway | Factor in disproportionately prolonged recovery before defaulting to a high dose |
Primary sources checked for this guide:
- April MD, et al. Rocuronium dose and first-attempt intubation success in the critically ill: secondary analysis of two multicenter trials. Am J Respir Crit Care Med. 2026;aamag203. doi:10.1093/ajrccm/aamag203.
- April MD, et al. Presented at American Thoracic Society International Conference, session B83 AJRCCM/NEJM/JAMA critical care, May 15-20, 2026, Orlando.
- Levin NM, Fix ML, April MD, Arana AA, Brown CA; NEAR Investigators. The association of rocuronium dosing and first-attempt intubation success in adult emergency department patients. CJEM. 2021;23(4):518-527.
- Levin NM, et al. The impact of rocuronium dose on first-attempt intubation success. Ann Emerg Med. 2019;74(4):S16 (research forum abstract).
- Rocuronium dosing for rapid sequence intubation: a retrospective analysis in ED and ICU settings. Reviewed via ScienceDirect, 2026.
- Casey JD, Semler MW, et al. DirEct versus VIdeo LaryngosCopE (DEVICE) trial protocol and statistical analysis plan. medRxiv, 2022 (trial background).
- Association of two preoxygenation approaches with hypoxemia during tracheal intubation: a secondary analysis of PREOXI/DEVICE. Reviewed via ScienceDirect, 2025 (trial background).
- Bevan DR, et al. Onset and duration of action of rocuronium — from tracheal intubation, through intense block to complete recovery. PubMed, 2001 (dose-response pharmacokinetics).
- Efficacy and safety of sugammadex for reversal of profound, high-dose rocuronium-induced neuromuscular blockade. Reviewed via ScienceDirect, dose-dependent reversal kinetics.
- Rocuronium monograph, onset/duration by dose and special populations. Drugs.com; StatPearls, reviewed 2024-2025.